BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
下载
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [41] Patients' Preferences for the Treatment of Moderate to Severe Rheumatoid Arthritis
    Hauber, A. Brett
    Poulos, Christine
    Gonzalez, Juan Marcos
    Ogale, Sarika
    Moawad, Dalia
    Turpcu, Adam
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S173 - S173
  • [42] A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
    Magnolo, Nina
    Kingo, Kulli
    Laquer, Vivian
    Browning, John
    Reich, Adam
    Szepietowski, Jacek C.
    Keefe, Deborah
    Mazur, Rafal
    Ghelani, Prayashi
    Forrer, Pascal
    Wraith, LindaAnn
    Patekar, Manmath
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 122 - 130
  • [43] SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
    Cohen, S.
    Alonso-Ruiz, A.
    Klimiuk, P. A.
    Lee, E.
    Peter, N.
    Sonderegger, I.
    Assudani, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 553 - 553
  • [44] Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
    Smolen, Josef S.
    Genovese, Mark C.
    Takeuchi, Tsutomu
    Hyslop, David L.
    Macias, William L.
    Rooney, Terence
    Chen, Lei
    Dickson, Christina L.
    Camp, Jennifer Riddle
    Cardillo, Tracy E.
    Ishii, Taeko
    Winthrop, Kevin L.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (01) : 7 - 18
  • [45] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
    Matucci-Cerinic, Marco
    Allanore, Yannick
    Kavanaugh, Arthur
    Buch, Maya H.
    Schulze-Koops, Hendrik
    Kucharz, Eugeniusz J.
    Woehling, Heike
    Babic, Goran
    Poetzl, Johann
    Davis, Adanna
    Schwebig, Arnd
    RMD OPEN, 2018, 4 (02):
  • [46] 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)
    Mease, PJ
    Choy, EHS
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Weinberg, MA
    RHEUMATOLOGY, 2005, 44 : I3 - I3
  • [47] Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China
    Wu, Bin
    Wilson, Alisa
    Wang, Fang-fang
    Wang, Su-li
    Wallace, Daniel J.
    Weisman, Michael H.
    Lu, Liang-jing
    PLOS ONE, 2012, 7 (10):
  • [48] A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease
    van Dyck, Christopher H.
    Tariot, Pierre N.
    Meyers, Barnett
    Resnick, E. Malca
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2007, 21 (02): : 136 - 143
  • [49] THE LORNET STUDY IN RUSSIAN FEDERATION: THE SAFETY OF TOCILIZUMAB IN THE TREATMENT MODERATE AND SEVERE RHEUMATOID ARTHRITIS
    Panasynk, E.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 947 - 948
  • [50] 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Taylor, Peter
    Genovese, Mark
    Keystone, Edward C.
    Drescher, Edit
    Berclaz, Pierre-Yves
    Lee, Chin
    Fidelus-Gort, Rosalind
    Schlichting, Douglas
    Beattie, Scott
    Luchi, Monica
    Macias, William
    RHEUMATOLOGY, 2013, 52 : 44 - 45
12345